Shin Nippon Biomedical Laboratories, Ltd. Share Price BOERSE MUENCHEN
Equities
YB3
JP3379950003
Biotechnology & Medical Research
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
8 EUR | 0.00% | -2.44% | -25.93% |
Sales 2024 | 26.45B 168M 155M 14.03B | Sales 2025 * | 30.5B 194M 179M 16.17B | Capitalization | 58.49B 372M 343M 31.02B |
---|---|---|---|---|---|
Net income 2024 | 5.53B 35.2M 32.46M 2.93B | Net income 2025 * | 4.3B 27.37M 25.23M 2.28B | EV / Sales 2024 | 2.39 x |
Net Debt 2024 * | 19.51B 124M 114M 10.35B | Net Debt 2025 * | 22.77B 145M 134M 12.08B | EV / Sales 2025 * | 2.66 x |
P/E ratio 2024 |
11.4
x | P/E ratio 2025 * |
13.6
x | Employees | - |
Yield 2024 |
3.29% | Yield 2025 * |
3.56% | Free-Float | 48.8% |
1 week | -2.44% | ||
Current month | -10.61% | ||
1 month | -10.11% | ||
3 months | -20.79% | ||
6 months | -20.79% | ||
Current year | -25.93% |
Managers | Title | Age | Since |
---|---|---|---|
Ryoichi Nagata
CEO | Chief Executive Officer | 65 | 01/81/01 |
Shinji Nitanda
DFI | Director of Finance/CFO | 55 | 01/02/01 |
Terumasa Hirai
CMP | Compliance Officer | - | 01/84/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Ryoichi Nagata
CEO | Chief Executive Officer | 65 | 01/81/01 |
Ichiro Nagata
BRD | Director/Board Member | 38 | 01/17/01 |
Sales & Marketing | 64 | 01/02/01 |
Date | Price | Change |
---|---|---|
29/24/29 | 8 | 0.00% |
28/24/28 | 8 | +1.91% |
27/24/27 | 7.85 | 0.00% |
24/24/24 | 7.85 | -0.63% |
23/24/23 | 7.9 | 0.00% |
Real-time BOERSE MUENCHEN, May 29, 2024 at 02:43 pm IST
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+54.05% | 58.71B | |
-2.02% | 41.31B | |
+37.38% | 39.2B | |
-10.22% | 27.4B | |
+13.42% | 26.55B | |
-21.60% | 18.98B | |
+2.89% | 12.51B | |
+22.40% | 11.94B | |
+27.49% | 12.08B |
- Stock Market
- Equities
- 2395 Stock
- YB3 Stock